EP1017682A4 - NEW ANGIOGENESIS INHIBITORS - Google Patents
NEW ANGIOGENESIS INHIBITORSInfo
- Publication number
- EP1017682A4 EP1017682A4 EP98948427A EP98948427A EP1017682A4 EP 1017682 A4 EP1017682 A4 EP 1017682A4 EP 98948427 A EP98948427 A EP 98948427A EP 98948427 A EP98948427 A EP 98948427A EP 1017682 A4 EP1017682 A4 EP 1017682A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- new angiogenesis
- new
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6015197P | 1997-09-26 | 1997-09-26 | |
| US60151P | 1997-09-26 | ||
| GBGB9810544.8A GB9810544D0 (en) | 1998-05-15 | 1998-05-15 | Novel angiogenesis inhibitors |
| GB9810544 | 1998-05-15 | ||
| PCT/US1998/019789 WO1999016755A1 (en) | 1997-09-26 | 1998-09-22 | Novel angiogenesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1017682A1 EP1017682A1 (en) | 2000-07-12 |
| EP1017682A4 true EP1017682A4 (en) | 2000-11-08 |
Family
ID=26313694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98948427A Withdrawn EP1017682A4 (en) | 1997-09-26 | 1998-09-22 | NEW ANGIOGENESIS INHIBITORS |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1017682A4 (en) |
| JP (1) | JP2001518470A (en) |
| AU (1) | AU744939B2 (en) |
| CA (1) | CA2303830A1 (en) |
| WO (1) | WO1999016755A1 (en) |
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1178791A2 (en) * | 1999-05-07 | 2002-02-13 | Johns Hopkins University School of Medicine | The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| UA74803C2 (en) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
| UA75055C2 (en) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
| EP1255750A1 (en) * | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| JP2001302667A (en) * | 2000-04-28 | 2001-10-31 | Bayer Ag | Imidazopyrimidine derivative and triazolopyrimidine derivative |
| CN1307173C (en) | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | Pyrimidinamines as modulators of angiogenesis |
| SV2007000775A (en) | 2001-01-05 | 2007-03-15 | Pfizer | ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR |
| RU2259825C9 (en) | 2001-06-18 | 2006-04-10 | БиоДием Лимитед | Substances of antimicrobial, antifungoid and antiprotozoan activities |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| EP1460067A4 (en) * | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCTION OF THE DERIVATIVE, AND USE THEREOF |
| JP2005527511A (en) | 2002-03-01 | 2005-09-15 | ファイザー インコーポレイテッド | Indolyl-urea derivatives of thienopyridine useful as anti-angiogenic agents and methods of use thereof |
| CA2476594C (en) | 2002-03-05 | 2012-10-09 | Transtech Pharma, Inc. | Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| PA8580301A1 (en) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
| MXPA05004754A (en) | 2002-11-13 | 2005-08-02 | Chiron Corp | Methods of treating cancer and related methods. |
| SI1585743T1 (en) | 2002-12-19 | 2007-08-31 | Pfizer | 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
| CN103265477B (en) | 2003-02-26 | 2017-01-11 | 苏根公司 | Aminoheteroaryl compounds as protein kinase inhibitors |
| HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
| ATE412655T1 (en) | 2003-08-29 | 2008-11-15 | Pfizer | THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS |
| AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
| JP4503022B2 (en) | 2003-12-23 | 2010-07-14 | ファイザー・インク | New quinoline derivatives |
| EP1711496A4 (en) | 2004-01-28 | 2009-02-11 | Smithkline Beecham Corp | Thiazole compounds |
| CN1960731B (en) | 2004-02-20 | 2011-12-07 | 诺华疫苗和诊断公司 | Method for regulating inflammatory and metastatic processes |
| EP1756054B1 (en) | 2004-06-01 | 2010-03-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| RU2007101509A (en) | 2004-06-17 | 2008-07-27 | Уайт (Us) | METHOD FOR PRODUCING HORMONE RECEPTOR ANTAGONISTS RELEASING GONADOTROPINE |
| MXPA06014798A (en) | 2004-06-17 | 2007-06-22 | Wyeth Corp | Gonadotropin releasing hormone receptor antagonists. |
| CN101014365B (en) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| PL1786785T3 (en) | 2004-08-26 | 2010-08-31 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinases |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| DOP2006000051A (en) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | VEGF-R2 INHIBITORS AND METHODS |
| WO2006105488A2 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| EP2444421A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| EP1904480A2 (en) | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| CN101517068B (en) | 2005-09-07 | 2017-02-08 | 安进弗里蒙特公司 | Human monoclonal antibodies to activin receptor-like kinase-1 |
| JP5055284B2 (en) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors |
| ES2368416T3 (en) | 2005-11-30 | 2011-11-17 | F. Hoffmann-La Roche Ag | PROCEDURE FOR THE SYNTHESIS OF 3-AMINO-1-ARILPROPIL-INDOLES. |
| ES2329413T3 (en) | 2005-11-30 | 2009-11-25 | F. Hoffmann-La Roche Ag | 3-AMINO-2-ARILPROPIL AZAINDOLES AND USES OF THE SAME. |
| BRPI0619263A2 (en) | 2005-11-30 | 2011-09-27 | Hoffmann La Roche | 3-amino-1-arylpropyl indoles and aza-substituted indoles, methods for preparing them, pharmaceutical composition and use of said indoles |
| AR059898A1 (en) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS |
| MX2008013990A (en) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof. |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| HRP20130649T1 (en) | 2007-09-07 | 2013-08-31 | Agensys, Inc. | Antibodies and related molecules that bind to 24p4c12 proteins |
| DE602008004794D1 (en) | 2007-09-14 | 2011-03-10 | Addex Pharmaceuticals Sa | 1 ', 3'-DISUBSTITUTED 4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-Ä1,4'-UPBIPYRIDINYL-2'-ONE |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| WO2010030360A1 (en) * | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| JP5836125B2 (en) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof |
| CN102232074B (en) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519281A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
| US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| AR076861A1 (en) | 2009-05-12 | 2011-07-13 | Addex Pharma Sa | DERIVATIVES OF 1,2,4-TRIAZOLO (4,3-A) PIRIDINE AND ITS USE AS POSITIVE ALOSTERIC MODULATORS OF MGLUR2 RECEIVERS |
| WO2010130422A1 (en) | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US20110076271A1 (en) | 2009-07-13 | 2011-03-31 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| EP2459191A1 (en) | 2009-07-31 | 2012-06-06 | OSI Pharmaceuticals, LLC | Mtor inhibitor and angiogenesis inhibitor combination therapy |
| WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
| JP2013504595A (en) | 2009-09-11 | 2013-02-07 | ジェネンテック， インコーポレイテッド | Methods for identifying patients with increased likelihood of response to anticancer drugs |
| MX2012002909A (en) | 2009-09-17 | 2012-04-19 | Hoffmann La Roche | METHODS AND COMPOSITIONS FOR USE IN DIAGNOSIS OF PATIENTS WITH CANCER. |
| TWI517850B (en) | 2009-09-30 | 2016-01-21 | Ｖｔｖ治療有限責任公司 | Substituted imidazole derivatives and methods of use thereof |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| JP5745283B2 (en) | 2010-02-12 | 2015-07-08 | ファイザー・インク | 8-Fluoro-2- {4-[(methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-cd] indol-6-one salts and many Form |
| WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| CN104689314B (en) | 2010-06-16 | 2018-02-02 | 高等教育联邦系统-匹兹堡大学 | Antibody of endoplasmin and application thereof |
| CN103180737A (en) | 2010-07-19 | 2013-06-26 | 霍夫曼-拉罗奇有限公司 | Method of identifying patients with increased likelihood of responding to anticancer therapy |
| WO2012010549A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| SG187592A1 (en) | 2010-07-23 | 2013-03-28 | Univ Boston | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| ES2543151T3 (en) | 2010-10-20 | 2015-08-17 | Pfizer Inc | 2-Pyridine derivatives as Smoothened receptor modulators |
| ES2552455T3 (en) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| ES2724801T3 (en) | 2011-04-19 | 2019-09-16 | Pfizer | Combinations of anti-4-1BB antibodies and ADCC inducing antibodies for cancer treatment |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| PT3409278T (en) | 2011-07-21 | 2020-12-18 | Sumitomo Dainippon Pharma Oncology Inc | Heterocyclic protein kinase inhibitors |
| CA2847540C (en) | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| WO2013050725A1 (en) | 2011-10-04 | 2013-04-11 | King's College London | Ige anti -hmw-maa antibody |
| BR112014011115A2 (en) | 2011-11-08 | 2017-06-13 | Pfizer | Methods for treating inflammatory disorders using anti-csf antibodies |
| KR20130076046A (en) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | Novel imidazopyridine derivatives as a tyrosine kinase inhibitor |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP6407504B2 (en) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Method for inhibiting constitutively active phosphorylated FLT3 kinase |
| US11642340B2 (en) | 2012-09-26 | 2023-05-09 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| KR20140040594A (en) | 2012-09-26 | 2014-04-03 | 아로그 파마슈티칼스, 엘엘씨 | Method of inhibiting mutant c-kit |
| US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| GB201223265D0 (en) * | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| ES2738493T3 (en) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors. |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
| SMT201900545T1 (en) | 2014-01-21 | 2019-11-13 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| PH12019500127B1 (en) | 2014-01-21 | 2022-05-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2015149720A1 (en) | 2014-04-04 | 2015-10-08 | Crown Bioscience, Inc.(Taicang) | Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| KR20160149256A (en) | 2014-04-30 | 2016-12-27 | 화이자 인코포레이티드 | Cycloalkyl-linked diheterocycle derivatives |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| EP3473271B1 (en) | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
| EP3233829B1 (en) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
| HK1251655A1 (en) | 2015-04-20 | 2019-02-01 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| CN107709344B (en) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | Nucleoside analogs for the treatment of Flaviviridae and cancer |
| EP4086264B1 (en) | 2015-05-18 | 2023-10-25 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| US10568887B2 (en) | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| US10730842B2 (en) | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| WO2017096165A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| PE20191238A1 (en) | 2016-11-02 | 2019-09-11 | Arog Pharmaceuticals Inc | CRENOLANIB TO TREAT MUTATIONS ASSOCIATED WITH PROLIFERATIVE DISORDERS WITH MUTATED FLT3 |
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| MX2019007332A (en) | 2016-12-19 | 2019-11-18 | Tolero Pharmaceuticals Inc | Profiling peptides and methods for sensitivity profiling. |
| JP7196160B2 (en) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib |
| WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
| AU2019391097B2 (en) | 2018-12-04 | 2025-07-03 | Sumitomo Pharma America, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| CN110840893A (en) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | Pharmaceutical composition containing clainib and application thereof |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
| EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| US11465998B2 (en) | 2019-04-25 | 2022-10-11 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
| US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| WO2022090547A1 (en) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production of carotenoids by fermentation |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
| JP2023063189A (en) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | Crenolanib for Treating FLT3 Mutant Proliferative Disorders Relapsed/Refractory to Previous Therapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563001A1 (en) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazole compounds, their preparation and use |
| EP0616807A1 (en) * | 1993-03-24 | 1994-09-28 | Neurosearch A/S | Benzimidazole useful in the treatment of central nervous system disorders |
| EP0635507A1 (en) * | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
| WO1998017651A1 (en) * | 1996-10-21 | 1998-04-30 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators |
-
1998
- 1998-09-22 EP EP98948427A patent/EP1017682A4/en not_active Withdrawn
- 1998-09-22 CA CA002303830A patent/CA2303830A1/en not_active Abandoned
- 1998-09-22 JP JP2000513841A patent/JP2001518470A/en not_active Withdrawn
- 1998-09-22 WO PCT/US1998/019789 patent/WO1999016755A1/en not_active Ceased
- 1998-09-22 AU AU95003/98A patent/AU744939B2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563001A1 (en) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazole compounds, their preparation and use |
| EP0616807A1 (en) * | 1993-03-24 | 1994-09-28 | Neurosearch A/S | Benzimidazole useful in the treatment of central nervous system disorders |
| EP0635507A1 (en) * | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
| WO1998017651A1 (en) * | 1996-10-21 | 1998-04-30 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9916755A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2303830A1 (en) | 1999-04-08 |
| JP2001518470A (en) | 2001-10-16 |
| AU744939B2 (en) | 2002-03-07 |
| EP1017682A1 (en) | 2000-07-12 |
| AU9500398A (en) | 1999-04-23 |
| WO1999016755A1 (en) | 1999-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1017682A4 (en) | NEW ANGIOGENESIS INHIBITORS | |
| EP0984692A4 (en) | NEW ANGIOGENESIS INHIBITORS | |
| EP0934305A4 (en) | INTEGRINE ANTAGONISTS | |
| EP1147107A4 (en) | ANGIOGENESIS INHIBITORS | |
| EP0946164A4 (en) | INTEGRINE ANTAGONISTS | |
| NO996108D0 (en) | 9 oksinerytromycinderivater | |
| NO963261D0 (en) | Runners | |
| DE69625622D1 (en) | Angiogenesis inhibitors | |
| DK0869898T3 (en) | Pour Garment | |
| NO982473D0 (en) | 5'Deoxy-cytidine derivative | |
| NO992059D0 (en) | 2 metoksyfenylpiperazinderivater | |
| NO20002555D0 (en) | Extension | |
| DE59706428D1 (en) | circuitry | |
| PT787861E (en) | SHIRT | |
| FI973885A0 (en) | Foerfarande och anordning i pappermaskinens / kartongmaskinens torkningsparti | |
| DE69926606D1 (en) | PLAZENTAPROTEIN 13 | |
| BR9709521A (en) | "3-Cyanoaryl-pyrazoles" | |
| FR2760746B3 (en) | NEW ACYLAMINOACIDS | |
| ATE243218T1 (en) | 2''-DEOXYHYGROMYCIN DERIVATIVES | |
| NO996127D0 (en) | 13-dihydro-3'-aziridino-anthracyclines | |
| FR2735986B3 (en) | HALTERA EXTENSION | |
| SE9700389D0 (en) | Hookah "Karlsborgpipan" | |
| KR970056542U (en) | necktie | |
| ITCS970006V0 (en) | "1 M" | |
| BR9606017A (en) | "Enrotrilan" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20000426 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000426;LT PAYMENT 20000426;LV PAYMENT 20000426;MK PAYMENT 20000426;RO PAYMENT 20000426;SI PAYMENT 20000426 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20000922 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030227 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040813 |